azd2184
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2008 (NCT00692705)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Amyloid beta A4 proteinINHIBITOR
APP inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 2-(6-(methylamino)pyridin-3-yl)-1,3-benzothiazol-6-ol
- azd2184
- azd2184
- azd2184
- azd 2184
- azd-2184
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00838877 | Phase 1 | Jan 1, 2009 | AstraZeneca, Karolinska Institute |
| NCT00692705 | Phase 1 | Jan 1, 2008 | AstraZeneca, Karolinska Institute |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 2 | 2 | 1 | 2008 |
| Karolinska Institute | Academic/Hospital | 2 | 0 | 1 | 2008 |
2 organizations
Page 1 / 1